Altre lingue Akili, Inc.

Azioni

AKLI

US00974B1070

Prezzo di chiusura Nasdaq Altri mercati azionari 00:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
0,2435 ^USD	-1,81%		+2,31%	-50,01%

29/02	Akili, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
29/02	Akili, Inc. riporta i risultati degli utili per il quarto trimestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	29/02
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02
Sector Update: Health Care Stocks Ease Late Afternoon	26/02
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	26/02
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	26/02
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan	26/02
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	26/02
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates	21/02
Akili Appoints John Spinale to the Board and Audit Committee	21/02
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	05/01
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024	05/01
Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board	20/12
EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17	18/12
Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration	18/12
Ubongo Takes Digital Literacy Campaign to Burera	21/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Akili, Inc.

Azioni

AKLI

US00974B1070

Altre lingue

Filtri